Extension of overall Survival of patients with SCLC by Imfinzi Combo Therapy

According to the results of phase III clinical trial, by the addition of Imfinzi to the standard first-line chemotherapy resulted in the clinically meaningful extension in the overall survival rate of the patients who have advanced small cell lung cancer (SCLC).

The open-label, global CASPIAN trial is testing AstraZeneca’s Imfinzi in combination with chemotherapies; etoposide & either carboplatin or cisplatin or tremelimumab & chemotherapy with Imfinzi, compared with alone chemotherapy in patients with extensive-stage of SCLC, which means that cancer has spread to the other parts of the body or lungs.

The patients were given up to 4 cycles of chemotherapy, whereas those in the control group had up to 6 cycles of prophylactic cranial irradiation (which is employed to kill the tumor cells) and chemotherapy.

Tolerability and Safety of the Imfinzi combination approaches were aligned with the known safety profiles of the various medicines. AstraZeneca has planned to present these results at a forthcoming medical meeting.

CASPIAN is being conducted in over 200 centers in 22 countries inclusive of Asia, South America, the United South, Europe, and the Middle East. The final analysis will be assessing the benefits of combining chemotherapy with Imfinzi and tremelimumab.

The Executive Vice President of AstraZeneca ‘s oncology research and development, Jose Baselga said in a press release that the phase 3 CASPIAN results offer a new ray of hope for the patients for whom there is an urgent requirement of new medicines. This is the first trial that offers the flexibility of combining immunotherapy with various platinum-based regimens in small cell lung cancer, advancing the treatment options.

Both Imfinzi & the investigational medicine ‘tremelimumab’ belong to a form of cancer antibody treatment which is known as the immune checkpoint inhibitors.

, , , , , , , , , , , ,